Ep 17 - A Conversation with Carsten Brunn of Cartesian Therapeutics

Carsten Brunn, Ph.D. serves as President and Chief Executive Officer of Cartesian Therapeutics. Prior to Cartesian’s merger with Selecta in November 2023, Carsten served in this role at Selecta. Before joining Selecta, he was the President of Pharmaceuticals for the Americas Region at Bayer and a member of the Global Pharmaceutical Executive Committee. Before being appointed to that role in 2017, he was the President of Bayer Pharmaceuticals in Japan, a role he had held since 2013. Carsten also served as the Chairman of the European federation of Pharmaceutical Industries and Associations (EFPIA) Japan, an organization representing innovative pharmaceutical companies in Japan.
Over the last 25 years, Carsten has held a number of senior leadership positions in Europe, Asia, and the United States at leading companies such as Eli Lilly, Novartis, Basilea, and Bausch & Lomb. Carsten graduated from the University of Freiburg in Germany with a Master of Science in Pharmaceutical Sciences. In addition, he studied at the University of Washington under a research scholarship. He received his Ph.D. in Chemistry from the University of Hamburg, Germany, and completed his executive education at London Business School. Carsten serves as a director on the board of Surface Oncology.
IMPORTANT: The views expressed in this promotion are based on personal opinions and should not be considered investment advice. Scheer Partners’ employs individuals that own shares in Cartesian Therapeutics stock.

[@newyorksilverking9394]

Wait...what ??....Well capitalized through the second half of 2026 ??...They did a 130 million dollar pipe today that torpedoed the stock..This literally 2 weeks after his comment..I would scrub this video stat..Rumors of a class action bubbling..